Nanomedicine News RSS Feed - Nanomedicine

New Insight Report on Cancer Nanomedicine Market

New Insight Report on Cancer Nanomedicine Market

Research and Markets has announced the addition of the "Cancer Nanomedicine Market & Pipeline Insight 2015" report to their offering. [More]
University of Manchester Scientists Selectively Target and Neutralize Cancer Stem Cells Using Graphene

University of Manchester Scientists Selectively Target and Neutralize Cancer Stem Cells Using Graphene

University of Manchester scientists have used graphene to target and neutralise cancer stem cells while not harming other cells. [More]
Innovative Approach Combines Nanotechnology and Molecular Biology to Tackle Brain Cancer

Innovative Approach Combines Nanotechnology and Molecular Biology to Tackle Brain Cancer

There are no effective available treatments for sufferers of Glioblastoma multiforme (GBM), the most aggressive and devastating form of brain tumor. The disease, always fatal, has a survival rate of only 6-18 months. [More]
UCLA Researchers Devise Optimized Nanodrug Combination Approach

UCLA Researchers Devise Optimized Nanodrug Combination Approach

In greater than 90 percent of cases in which treatment for metastatic cancer fails, the reason is that the cancer is resistant to the drugs being used. To treat drug-resistant tumors, doctors typically use multiple drugs simultaneously, a practice called combination therapy. And one of their greatest challenges is determining which ratio and combination -- from the large number of medications available -- is best for each individual patient. [More]
Rapid Diagnostic Test for Ebola and Other Fevers Using Multicolored Nanoparticles

Rapid Diagnostic Test for Ebola and Other Fevers Using Multicolored Nanoparticles

When diagnosing a case of Ebola, time is of the essence. However, existing diagnostic tests take at least a day or two to yield results, preventing health care workers from quickly determining whether a patient needs immediate treatment and isolation. [More]
Tiny Molecule Holds Potential to Decrease Likelihood of Alcohol-Related Cancers in At-Risk Population

Tiny Molecule Holds Potential to Decrease Likelihood of Alcohol-Related Cancers in At-Risk Population

Researchers at the Stanford University School of Medicine have found that by changing the selectivity of an enzyme, a small molecule could potentially be used to decrease the likelihood of alcohol-related cancers in an at-risk population. [More]
DNA Minicircles Show Promise for Early Detection of Cancer

DNA Minicircles Show Promise for Early Detection of Cancer

Imagine: You pop a pill into your mouth and swallow it. It dissolves, releasing tiny particles that are absorbed and cause only cancerous cells to secrete a specific protein into your bloodstream. Two days from now, a finger-prick blood sample will expose whether you've got cancer and even give a rough idea of its extent. [More]
Researchers Devise Innovative Clot-Busting Technique Using Magnetic Nanoparticles

Researchers Devise Innovative Clot-Busting Technique Using Magnetic Nanoparticles

By loading magnetic nanoparticles with drugs and dressing them in biochemical camouflage, Houston Methodist researchers say they can destroy blood clots 100 to 1,000 times faster than a commonly used clot-busting technique. [More]
Celsion Presents Data on GEN-1 DNA-Based Immunotherapy for Advanced Platinum-Resistant and Recurrent Ovarian Cancer

Celsion Presents Data on GEN-1 DNA-Based Immunotherapy for Advanced Platinum-Resistant and Recurrent Ovarian Cancer

Celsion Corporation, a fully-integrated oncology company focused on the development of a high potential portfolio of innovative cancer treatments, today presented clinical and preclinical data demonstrating the safety, biological activity and clinical benefits of GEN-1, its DNA-based immunotherapy, as a single agent in advanced platinum-resistant and recurrent ovarian cancer patients, at the Molecular Medicine TRI-Conference in San Francisco. These data provide support for advancing GEN-1 into clinical development in the front-line setting. [More]
CeloNova Completes Enrollment in IDE Trial of COBRA PzF Stent with Polyzene-F Nano-Coating

CeloNova Completes Enrollment in IDE Trial of COBRA PzF Stent with Polyzene-F Nano-Coating

CeloNova BioSciences, Inc. announced completion of patient enrollment in the global, multi-center IDE trial for its COBRA PzF stent. Completed enrollment was ahead of schedule and supports submission for FDA approval of the novel COBRA PzF stent with its advanced, nano-thin coating of Polyzene™-F polymer. [More]